Qin Qin, Ge Xiaolin, Wang Xin, Wang Lan, Li Chen, Chen Junqiang, Wang Xiaomin, Zhao Yidian, Zhang Wencheng, Wang Ping, Pang Qingsong, Zhang Kaixian, Li Ling, Hu Miaomiao, Hao Chongli, Li Gaofeng, Xu Yonggang, Qiao Xueying, Zhou Zhiguo, Zhu Shuchai, Shen Wenbin, Wang Yati, Lu Na, Liu Miaoling, Qie Shuai, Han Chun, Xiao Zefen, Sun Xinchen
Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Oncol. 2020 Oct 6;10:580450. doi: 10.3389/fonc.2020.580450. eCollection 2020.
To evaluate long-term outcome and prognostic factors of stage III esophageal cancer after definitive radiotherapy using three dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) techniques. Patients with T3N1M0/T4N0-1M0 esophageal squamous cell carcinoma (ESCC) treated with definitive radiotherapy from 2002 to 2016 in 10 Chinese medical centers were retrospectively analyzed. Overall survival (OS) and progression-free survival (PFS) rates were calculated. Prognostic factors were analyzed by Log-rank test and multivariable Cox model. Survival data of 1,450 patients were retrospectively collected. With a median follow-up time of 65.9 months, 1-, 3-, and 5-year OS rates were 69.3, 36.7, and 27.7%, respectively, and PFS rates were 58.6, 32.7, and 27.4%, respectively. Univariable analyses showed that gender, age, lesion location, lesion length, largest tumor diameter, lymph node metastasis, gross tumor volume, EQD2, short-term response, and concurrent chemotherapy were prognostic factors for OS. Multivariable analyses showed that lesion location, T-classification, GTV size, EQD2, and short-term response to RT were independent prognostic factors for OS, and tumor diameter, GTV size, and short-term response were independent prognostic factors for PFS. This study demonstrated that definitive radiotherapy using 3DCRT and IMRT provides promising outcomes for locally advanced ESCC.
评估采用三维适形放疗(3DCRT)或调强放疗(IMRT)技术进行根治性放疗后Ⅲ期食管癌的长期疗效和预后因素。回顾性分析了2002年至2016年期间在中国10家医疗中心接受根治性放疗的T3N1M0/T4N0 - 1M0食管鳞状细胞癌(ESCC)患者。计算总生存(OS)率和无进展生存(PFS)率。通过Log-rank检验和多变量Cox模型分析预后因素。回顾性收集了1450例患者的生存数据。中位随访时间为65.9个月,1年、3年和5年的OS率分别为69.3%、36.7%和27.7%,PFS率分别为58.6%、32.7%和27.4%。单变量分析显示,性别、年龄、病变部位、病变长度、最大肿瘤直径、淋巴结转移、肿瘤总体积、等效剂量(EQD2)、短期反应和同步化疗是OS的预后因素。多变量分析显示,病变部位、T分期、肿瘤总体积(GTV)大小、EQD2和放疗短期反应是OS的独立预后因素,肿瘤直径、GTV大小和短期反应是PFS的独立预后因素。本研究表明,采用3DCRT和IMRT进行根治性放疗为局部晚期ESCC提供了有前景的疗效。